PL369454A1 - 2-amino-6-(2,4,5-podstawione-fenylo)-pirydyny do stosowania jako inhibitory syntazy tlenku azotu - Google Patents

2-amino-6-(2,4,5-podstawione-fenylo)-pirydyny do stosowania jako inhibitory syntazy tlenku azotu

Info

Publication number: PL369454A1
Authority: PL; Poland
Prior art keywords: pyridine; phenyl; amino; substituted; nitric oxide
Prior art date: 2001-10-10

Application number

PL02369454A

Other languages

English (en)

Inventor

John Adams Lowe Iii

Robert Alfred Volkmann

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-10

Filing date

2002-09-24

Publication date

2005-04-18

2002-09-24 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2005-04-18 Publication of PL369454A1 publication Critical patent/PL369454A1/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Psychology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)

PL02369454A 2001-10-10 2002-09-24 2-amino-6-(2,4,5-podstawione-fenylo)-pirydyny do stosowania jako inhibitory syntazy tlenku azotu PL369454A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US32825301P	2001-10-10	2001-10-10

Publications (1)

Publication Number	Publication Date
PL369454A1 true PL369454A1 (pl)	2005-04-18

Family

ID=23280189

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL02369454A PL369454A1 (pl)	2001-10-10	2002-09-24	2-amino-6-(2,4,5-podstawione-fenylo)-pirydyny do stosowania jako inhibitory syntazy tlenku azotu

Country Status (37)

Country	Link
EP (1)	EP1434624B1 (pl)
JP (1)	JP2005506337A (pl)
KR (1)	KR20040053157A (pl)
CN (1)	CN1568207A (pl)
AP (1)	AP2004003003A0 (pl)
AR (1)	AR036763A1 (pl)
AT (1)	ATE344089T1 (pl)
BG (1)	BG108669A (pl)
BR (1)	BR0213193A (pl)
CA (1)	CA2463364A1 (pl)
CZ (1)	CZ2004450A3 (pl)
DE (1)	DE60215837T2 (pl)
DO (1)	DOP2002000467A (pl)
EA (1)	EA007074B1 (pl)
EC (1)	ECSP045055A (pl)
EE (1)	EE200400085A (pl)
ES (1)	ES2275917T3 (pl)
GT (1)	GT200200206A (pl)
HN (1)	HN2002000289A (pl)
HR (1)	HRP20040260A2 (pl)
HU (1)	HUP0401678A3 (pl)
IL (1)	IL161089A0 (pl)
IS (1)	IS7171A (pl)
MA (1)	MA27074A1 (pl)
MX (1)	MXPA04002313A (pl)
NO (1)	NO20041411L (pl)
NZ (1)	NZ531591A (pl)
OA (1)	OA12664A (pl)
PA (1)	PA8556101A1 (pl)
PE (1)	PE20030478A1 (pl)
PL (1)	PL369454A1 (pl)
PY (1)	PY0223361A (pl)
SK (1)	SK1642004A3 (pl)
TN (1)	TNSN04057A1 (pl)
UY (1)	UY27476A1 (pl)
WO (1)	WO2003030993A1 (pl)
ZA (1)	ZA200401747B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030232739A1 (en) *	2001-08-15	2003-12-18	Pfizer Inc.	Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist
US20080070952A1 (en) *	2005-02-21	2008-03-20	Proximagen Ltd.,	Inhibition or Treatment of Dyskinesia
US9540361B2 (en) *	2010-12-24	2017-01-10	Merck Sharp & Dohme B.V.	N-substituted azetidine derivatives
RU2637503C1 (ru) *	2016-12-30	2017-12-05	Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский государственный университет" (ТГУ, НИ ТГУ)	Способ получения n2-метилдезоксигуанозина

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA49006C2 (uk) *	1996-03-29	2002-09-16	Файзер Інк.	Похідні 6-фенілпіридил-2-аміну, фармацевтична композиція, спосіб інгібування синтази оксиду нітрогену у ссавців та спосіб лікування
WO1998034919A1 (en) *	1997-02-10	1998-08-13	Pfizer Products Inc.	2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines
PL358538A1 (pl) *	1999-05-21	2004-08-09	Pfizer Products Inc.	Nowe środki farmaceutyczne dla inbibitorów NOS

2002
- 2002-09-23 DO DO2002000467A patent/DOP2002000467A/es unknown
- 2002-09-24 CZ CZ2004450A patent/CZ2004450A3/cs unknown
- 2002-09-24 AP APAP/P/2004/003003A patent/AP2004003003A0/en unknown
- 2002-09-24 EP EP02775016A patent/EP1434624B1/en not_active Expired - Lifetime
- 2002-09-24 ES ES02775016T patent/ES2275917T3/es not_active Expired - Lifetime
- 2002-09-24 WO PCT/IB2002/003939 patent/WO2003030993A1/en not_active Ceased
- 2002-09-24 SK SK164-2004A patent/SK1642004A3/sk not_active Application Discontinuation
- 2002-09-24 OA OA1200400093A patent/OA12664A/en unknown
- 2002-09-24 BR BR0213193-5A patent/BR0213193A/pt not_active IP Right Cessation
- 2002-09-24 MX MXPA04002313A patent/MXPA04002313A/es active IP Right Grant
- 2002-09-24 IL IL16108902A patent/IL161089A0/xx unknown
- 2002-09-24 HR HRP20040260 patent/HRP20040260A2/hr not_active Application Discontinuation
- 2002-09-24 PL PL02369454A patent/PL369454A1/pl not_active Application Discontinuation
- 2002-09-24 HU HU0401678A patent/HUP0401678A3/hu unknown
- 2002-09-24 EE EEP200400085A patent/EE200400085A/xx unknown
- 2002-09-24 JP JP2003534022A patent/JP2005506337A/ja not_active Withdrawn
- 2002-09-24 AT AT02775016T patent/ATE344089T1/de not_active IP Right Cessation
- 2002-09-24 KR KR10-2004-7005248A patent/KR20040053157A/ko not_active Ceased
- 2002-09-24 CN CNA028200675A patent/CN1568207A/zh active Pending
- 2002-09-24 CA CA002463364A patent/CA2463364A1/en not_active Abandoned
- 2002-09-24 DE DE60215837T patent/DE60215837T2/de not_active Expired - Fee Related
- 2002-09-24 EA EA200400321A patent/EA007074B1/ru not_active IP Right Cessation
- 2002-09-24 NZ NZ531591A patent/NZ531591A/en unknown
- 2002-09-25 PY PY200200223361A patent/PY0223361A/es unknown
- 2002-10-04 PE PE2002000987A patent/PE20030478A1/es not_active Application Discontinuation
- 2002-10-08 AR ARP020103790A patent/AR036763A1/es unknown
- 2002-10-08 UY UY27476A patent/UY27476A1/es not_active Application Discontinuation
- 2002-10-09 HN HN2002000289A patent/HN2002000289A/es unknown
- 2002-10-10 GT GT200200206A patent/GT200200206A/es unknown
- 2002-10-10 PA PA20028556101A patent/PA8556101A1/es unknown
2004
- 2004-03-03 ZA ZA200401747A patent/ZA200401747B/en unknown
- 2004-03-04 IS IS7171A patent/IS7171A/is unknown
- 2004-04-02 NO NO20041411A patent/NO20041411L/no unknown
- 2004-04-06 BG BG108669A patent/BG108669A/xx unknown
- 2004-04-07 TN TNP2004000057A patent/TNSN04057A1/fr unknown
- 2004-04-08 EC EC2004005055A patent/ECSP045055A/es unknown
- 2004-04-08 MA MA27619A patent/MA27074A1/fr unknown

Also Published As

Publication number	Publication date
PY0223361A (es)	2004-04-01
OA12664A (en)	2006-06-19
SK1642004A3 (sk)	2005-04-01
NO20041411L (no)	2004-04-02
DE60215837D1 (de)	2006-12-14
KR20040053157A (ko)	2004-06-23
MA27074A1 (fr)	2004-12-20
HUP0401678A3 (en)	2007-05-02
HUP0401678A2 (hu)	2004-12-28
PE20030478A1 (es)	2003-06-06
ECSP045055A (es)	2004-05-28
EA200400321A1 (ru)	2004-08-26
UY27476A1 (es)	2003-05-30
DOP2002000467A (es)	2003-04-15
AR036763A1 (es)	2004-09-29
CA2463364A1 (en)	2003-04-17
BG108669A (bg)	2005-03-31
HRP20040260A2 (en)	2004-12-31
BR0213193A (pt)	2004-08-31
MXPA04002313A (es)	2005-04-08
ES2275917T3 (es)	2007-06-16
CN1568207A (zh)	2005-01-19
DE60215837T2 (de)	2007-05-16
EP1434624A1 (en)	2004-07-07
CZ2004450A3 (cs)	2005-03-16
PA8556101A1 (es)	2003-07-28
EP1434624B1 (en)	2006-11-02
JP2005506337A (ja)	2005-03-03
AP2004003003A0 (en)	2004-03-31
IS7171A (is)	2004-03-04
NZ531591A (en)	2006-04-28
ZA200401747B (en)	2005-03-03
HN2002000289A (es)	2002-12-03
GT200200206A (es)	2003-05-23
EA007074B1 (ru)	2006-06-30
WO2003030993A1 (en)	2003-04-17
IL161089A0 (en)	2004-08-31
TNSN04057A1 (fr)	2006-06-01
ATE344089T1 (de)	2006-11-15
EE200400085A (et)	2004-08-16

Legal Events

Date	Code	Title	Description
2010-07-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
ATE445615T1 (de)	2009-10-15	Pyrido(2,1-a)isochinolinderivative als dpp-iv- hemmer
NO20033288D0 (no)	2003-07-21	Anilinderivater som kan anvendes som fosfodiesterase 4- inhibitorer
DK1581532T3 (da)	2010-08-16	Pyrazolo-3,4-B pyridinforbindelser og deres anvendelse som phosphodiesterase inhibitorer
DK1265860T3 (da)	2005-07-11	Amidinoforbindelse og salte deraf, der er nyttige som nitrogenoxidsyntaseinhibitorer
NO20042097L (no)	2004-05-21	Naftyridinderivater, deres fremstilling og deres anvendelse som fosfodiesterase-isoenzym 4-(PDE4) inhibitorer.
NO20041293D0 (no)	2004-03-26	Alkyn-aryl-fosfodiesterase-4-inhibitorer
NO20041887L (no)	2004-05-07	Benzomidazoler anvendelige som proteinkinase-inhibitorer
NO20052887D0 (no)	2005-06-14	Pyridazinonderivater som GSK-3Beta inhibitorer.
PT1425270E (pt)	2006-07-31	Metodos para preparacao de inibidores de cetp.
NO20016201D0 (no)	2001-12-18	Tienopyrimidiner som fosfodiesteraseinhibitorer
DE50212399D1 (de)	2008-08-07	Haftklebemasse inbesondere für unpolare Oberflächen
AU2001282746A1 (en)	2002-02-18	Novel phenylheteroazetidines, useful as nitric oxide synthase inhibitors
NO20055518D0 (no)	2005-11-22	5-hydroksyindoler med N-oksidgrupper, anvendelse derav som fosfodiesterase 4-inhibitor
IS7171A (is)	2004-03-04	2-amínó-6-(2,4,5-setinn-fenýl)-pýridín til notkunar sem nituroxíð sýntasahindrar
ITTO20010694A0 (it)	2001-07-13	Metodo di crittografia.
NO20006042L (no)	2001-01-31	2-aminopyridiner inneholdende kondenserte ringsubstituenter som nitrogenoksyd-syntase-inhibitorer
ITRE20000040V0 (it)	2000-11-10	Pinza compensata per mandrino maschiatore.
ITTO20020015A0 (it)	2002-01-07	Attrezzo di molatura per applicazioni odontotecniche.
ITMO20020368A1 (it)	2004-06-30	Mezzi di finitura perfezionati.
ES1050360Y (es)	2002-07-16	Mango perfeccionado multiusos.
ZA200306119B (en)	2004-11-08	Trifluoromethylpurines as phosphodiesterase 4 inhibitors.
ES1048298Y (es)	2001-12-01	Semiblister corredera para herramientas, perfeccionado.
ES1050778Y (es)	2002-09-16	Mango perfeccionado.
DOP2001000274A (es)	2002-05-30	Inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas
ES1049820Y (es)	2002-05-16	Gafa perfeccionada.